By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ExonHit Therapeutics today said that it has been informed by RedPath Integrated Pathology that Medicare may discontinue coverage for RedPath's molecular diagnostic test for pancreatic cancer.

On Wednesday, ExonHit was told by RedPath that CMS contractor Highmark Medicare Services announced its intention to drop coverage of PathFinderTG-Pancreatic cancer, depending on an assessment of the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.